News
Australian sleep health giant Resmed has locked down an exemption from Donald Trump’s sweeping trade tariffs. Resmed produces ...
EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.
KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight ...
Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...
A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...
RBC Capital raised the firm’s price target on ResMed (RMD) to $255 from $247 and keeps a Sector Perform rating on the shares. The company’s Q3 ...
Resmed shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus forecast.
Resmed has named Salli Schwartz as chief investor relations officer, where she will lead the company’s global investor relations function and report to Mick Farrell, chairman of the board ...
Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback